Abstract

BackgroundThough the roles of microRNAs (miRNAs) in renal diseases have been extensively investigated, a thorough screening and comparison of miRNAs among different types of chronic kidney disease (CKD) has never been performed.MethodsThe intrarenal miRNAs were profiled from fresh kidney tissues of patients with biopsy-proven minimal change disease (MCD), focal segmental glomerular sclerosis (FSGS) and diabetic nephropathy (DN) by using microarray. Commonly dysregulated miRNAs were validated by real-time PCR using paraffin-embedded renal tissues from all three types of CKD patients as well as mouse unilateral ureteral obstruction (UUO) model. Two novel miRNAs were selected and annotations of their target genes were performed using GO and KEGG pathway enrichment analysis. Biological functions of three two candidate miRNAs were explored in TGF-β1-induced cell model using human kidney proximal tubular cells (HK-2).ResultsThe kidney biopsy samples of three disease types represent different levels of damage and fibrosis, which were the mildest in MCD, moderate in FSGS, and the most severe in DN. 116 miRNAs were identified to be commonly dysregulated, including 40 up-regulated and 76 down-regulated in CKD tissues as compared with healthy donor kidney biopsy tissues. Two novel miRNAs, hsa-miR-3607-3p and hsa-miR-4709-3p, were verified as consistently differentially expressed among all three types of patient samples as well as in mouse model. In vitro, hsa-miR-3607-3p was repressed while hsa-miR-4709-3p was induced by TGF-β1 treatment. Inhibition of hsa-miR-3607-3p or overexpression of hsa-miR-4709-3p promoted TGF-β1-induced migration and F-actin assembling in HK-2 cells, which are characteristics of epithelial–mesenchymal transition (EMT). Further study identified that ITGB8 and CALM3 were the bona fide target genes of hsa-miR-3607-3p and hsa-miR-4709-3p respectively.ConclusionsThe present identify a unique miRNAs profile that probably relates to the common fibrosis process of CKD. Results of our study suggest that hsa-miR-3607-3p and hsa-miR-4709-3p may represent as promising therapeutic targets against kidney fibrosis.

Highlights

  • Though the roles of microRNAs in renal diseases have been extensively investigated, a thorough screening and comparison of miRNAs among different types of chronic kidney disease (CKD) has never been performed

  • There is no significant difference among three groups regarding proteinuria, while serum albumin level was lower in minimal change disease (MCD) patients compared to focal segmental glomerular sclerosis (FSGS) and diabetic nephropathy (DN) subjects (Table 1)

  • MiRNA expression profile in kidney specimens of CKD patients Total 16 fresh kidney biopsy samples were analyzed for intra-renal miRNA expression profile by microarray screening and the results are presented in Fig. 2 and Additional file 5

Read more

Summary

Introduction

Though the roles of microRNAs (miRNAs) in renal diseases have been extensively investigated, a thorough screening and comparison of miRNAs among different types of chronic kidney disease (CKD) has never been performed. MicroRNAs (miRNAs) are small endogenous non-coding RNAs that are involved in a variety of pathophysiological processes, including development, fibrosis, and tumor [8, 9] They exert their biological functions mainly by post-transcriptionally regulating gene expression via base-pairing with the 3′ untranslated regions (3′ UTRs) of target mRNAs. Mounting evidence shows that miRNAs play an important role in renal diseases. A thorough screening and comparison of CKDrelated miRNAs by using biopsy samples from different types of kidney diseases has never been performed Another important issue is that considerable discrepancy regarding expression profiles as well as roles of candidate miRNAs in renal diseases exists among previous studies [21, 22]. Common miRNAs which changed consistently among three types of kidney diseases were selected for further functional studies

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call